查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1454729

免疫分析市场- 按技术（ELISA、CLIA、RIA）、产品（试剂和试剂盒、分析仪/仪器）、样本（血液、唾液、尿液）、应用（肿瘤学、心臟病学）、最终用途（医院和诊所、诊断实验室） ) - 全球预测，2024 - 2032

Immunoassay Market - By Technology (ELISA, CLIA, RIA), Product (Reagent & Kits, Analyzers/Instruments), Specimen (Blood, Saliva, Urine), Application (Oncology, Cardiology), End-use (Hospitals & Clinics, Diagnostic Labs) - Global Forecast, 2024 - 2032
出版日期: | 出版商: Global Market Insights Inc. | 英文 270 Pages | 商品交期: 2-3个工作天内

价格
简介目录

由于免疫分析技术的不断进步和对先进诊断的强劲需求，预计 2024 年至 2032 年全球免疫分析市场规模的CAGR将达到 5.3%。随着更灵敏、更特异的检测等不断创新，对复杂诊断工具的需求正在激增。最近，医疗保健提供者和患者越来越多地寻求针对各种疾病的准确有效的检测方法。对诊断精度的日益增长的需求加上快速的技术进步，为免疫分析技术的扩展创造了肥沃的土壤，因为它不断满足不断变化的医疗保健需求。例如，2023年7月，Fapon在2023年AACC展会期间向全球市场推出了最新的化学发光免疫分析系统Shine i8000/9000。

免疫分析产业分为技术、产品、样本、应用、最终用途和区域。

在应用方面，受先进癌症诊断和治疗监测需求不断增长的推动，到 2032 年，肿瘤学领域的市场份额将显着上升，复合CAGR为 6.2%。随着全球癌症发生率的上升，人们更加关注早期检测和个人化治疗，其中免疫测定在提供癌症生物标记的灵敏和特异性检测以进行及时干预方面发挥关键作用。随着肿瘤学领域的不断发展，对免疫分析技术的需求将激增，反映出对准确的癌症诊断和管理的迫切需求。

到 2032 年，免疫分析行业的诊断中心最终用途领域的CAGR将达到 6%。诊断实验室在医疗保健领域为各种疾病提供广泛的检测所发挥的重要作用推动了这一增长。对准确、快速诊断工具不断增长的需求正在加速诊断实验室的重要性，因为它们有能力快速提供高效、可靠的结果，使它们成为医疗保健生态系统的重要组成部分。对早期疾病检测和管理的日益关注将进一步增加对诊断实验室的偏好。

由于医疗保健支出增加、慢性病盛行率上升以及研发活动不断扩大，2024年至2032年亚太地区免疫分析市场规模将呈现6.1%的复合CAGR。中国和印度等国家的医疗保健产业正在显着成长，推动了对免疫分析技术的需求。亚太地区拥有庞大的人口基数和先进的医疗基础设施，将成为免疫分析产业扩张的重要贡献者。

目录

第 1 章：方法与范围

第 2 章：执行摘要

第 3 章：产业洞察

  • 产业生态系统分析
  • 产业影响力
    • 成长动力
      • 慢性病盛行率增加
      • 免疫分析技术的进步
      • 对现场检测的需求不断增长
      • 提高认识和筛检计划
    • 产业陷阱与挑战
      • 严格的监管框架
      • 与免疫测定相关的挑战
  • 成长潜力分析
  • 技术景观
  • 监管环境
  • 波特的分析
  • PESTEL分析

第 4 章：竞争格局

  • 介绍
  • 公司市占率分析
  • 竞争定位矩阵
  • 战略展望矩阵

第 5 章：市场估计与预测：按产品分类，2018 年 - 2032 年

  • 主要趋势
  • 试剂和试剂盒
    • ELISA 试剂和试剂盒
    • ELISPOT 试剂与试剂盒
    • 快速检测试剂和试剂盒
    • 蛋白质印迹试剂和试剂盒
    • 化学发光免疫分析试剂与试剂盒
    • 免疫萤光检测试剂及试剂盒
    • 其他试剂和试剂盒
  • 分析仪/仪器
    • 开放式系统
    • 封闭式系统

第 6 章：市场估计与预测：按技术划分，2018 年 - 2032 年

  • 主要趋势
  • 酵素连结免疫吸附测定法 (ELISA)
  • 化学发光免疫分析 (CLIA)
  • 放射免疫分析（RIA）
  • 免疫萤光分析 (IFA)
  • 蛋白质印迹法
  • 酵素连结免疫斑点法
  • 其他技术

第 7 章：市场估计与预测：按样本，2018 年 - 2032 年

  • 主要趋势
  • 血
  • 唾液
  • 尿
  • 其他标本

第 8 章：市场估计与预测：按应用，2018 - 2032

  • 主要趋势
  • 传染性疾病
  • 肿瘤学
  • 内分泌科
  • 心臟病学
  • 自体免疫疾病
  • 治疗药物监测
  • 其他应用

第 9 章：市场估计与预测：按最终用途，2018-2032 年

  • 主要趋势
  • 医院和诊所
  • 诊断中心
  • 研究和学术实验室
  • 家庭护理设置
  • 其他最终用户

第 10 章：市场估计与预测：按地区划分，2018 年 - 2032 年

  • 主要趋势
  • 北美洲
    • 我们
    • 加拿大
  • 欧洲
    • 德国
    • 英国
    • 法国
    • 西班牙
    • 义大利
    • 欧洲其他地区
  • 亚太地区
    • 日本
    • 中国
    • 印度
    • 澳洲
    • 韩国
    • 亚太地区其他地区
  • 拉丁美洲
    • 巴西
    • 墨西哥
    • 阿根廷
    • 拉丁美洲其他地区
  • 中东和非洲
    • 南非
    • 沙乌地阿拉伯
    • 阿联酋
    • 中东和非洲其他地区

第 11 章：公司简介

  • Abbott Laboratories
  • Agilent Technologies, Inc.
  • Becton Dickinson and Company
  • Bio-Rad Laboratories, Inc.
  • Danaher Corporation
  • F. Hoffmann-La Roche AG
  • Hologic Inc.
  • Luminex Corporation
  • PerkinElmer, Inc.
  • QIAGEN
  • Sysmex Corporation
  • Thermo Fisher Scientific Inc.
简介目录
Product Code: 8041

Global Immunoassay Market size is projected to record 5.3% CAGR from 2024 to 2032 due to rising strides in immunoassay technology and the strong demand for advanced diagnostics. With ongoing innovations, such as more sensitive and specific assays, the demand for sophisticated diagnostic tools is witnessing a surge. Of late, healthcare providers and patients are increasingly seeking accurate and efficient testing methods for various diseases. This growing need for precision in diagnostics coupled with rapid technological progress is creating a fertile ground for the expansion of immunoassay techniques as it continues to cater to the evolving healthcare demands. For instance, in July 2023, Fapon introduced its newest chemiluminescence immunoassay system, the Shine i8000/9000 for the global market during the 2023 AACC exhibition.

The immunoassay industry is classified into technology, product, specimen, application, end-use, and region.

In terms of application, the market share from the oncology segment will undergo a significant upturn by depicting a 6.2% CAGR through 2032, driven by the growing demand for advanced cancer diagnostics and treatment monitoring. With cancer rate on the rise globally, there is a heightened focus on early detection and personalized therapies, where immunoassays play a pivotal role in offering sensitive and specific detection of cancer biomarkers for timely interventions. As the oncology field continues to advance, the demand for immunoassay technologies will soar, reflecting the urgent need for accurate cancer diagnostics and management.

The diagnostic centers end-use segment in the immunoassay industry will experience 6% CAGR up to 2032. This is fueled by the essential role diagnostic labs play in healthcare for offering a wide array of tests for various diseases. The growing demand for accurate and rapid diagnostic tools is accelerating the significance of diagnostic labs as they have the ability to provide efficient and reliable results swiftly, making them a vital component in the healthcare ecosystem. The rising focus on early disease detection and management will further augment the preference for diagnostic labs.

Asia Pacific immunoassay market size will demonstrate a 6.1% CAGR from 2024 to 2032, attributed to the increasing healthcare expenditure, rising prevalence of chronic diseases, and expanding R&D activities. Countries like China and India are witnessing significant growth in the healthcare sector, propelling the demand for immunoassay technologies. With a vast population base and advancing healthcare infrastructure, Asia Pacific will emerge as a significant contributor to the immunoassay industry expansion.

Table of Contents

Chapter 1 Methodology & Scope

  • 1.1 Market scope & definitions
  • 1.2 Base estimates & calculations
  • 1.3 Data collection
  • 1.4 Forecast parameters
  • 1.5 Data validation
  • 1.6 Data sources
    • 1.6.1 Primary
    • 1.6.2 Secondary
      • 1.6.2.1 Paid sources
      • 1.6.2.2 Unpaid sources

Chapter 2 Executive Summary

  • 2.1 Industry 360 degree synopsis

Chapter 3 Industry Insights

  • 3.1 Industry ecosystem analysis
  • 3.2 Industry impact forces
    • 3.2.1 Growth drivers
      • 3.2.1.1 Increase in the prevalence of chronic conditions
      • 3.2.1.2 Advancements in immunoassay technologies
      • 3.2.1.3 Growing demand for point-of-care testing
      • 3.2.1.4 Rising awareness and screening programs
    • 3.2.2 Industry pitfalls & challenges
      • 3.2.2.1 Stringent regulatory framework
      • 3.2.2.2 Challenges associated with immunoassay
  • 3.3 Growth potential analysis
  • 3.4 Technological landscape
  • 3.5 Regulatory landscape
  • 3.6 Porter's analysis
    • 3.6.1 Supplier power
    • 3.6.2 Buyer power
    • 3.6.3 Threat of new entrants
    • 3.6.4 Threat of substitutes
    • 3.6.5 Industry rivalry
  • 3.7 PESTEL analysis

Chapter 4 Competitive Landscape, 2023

  • 4.1 Introduction
  • 4.2 Company market share analysis
  • 4.3 Competitive positioning matrix
  • 4.4 Strategy outlook matrix

Chapter 5 Market Estimates and Forecast, By Product, 2018 - 2032 ($ Mn)

  • 5.1 Key trends
  • 5.2 Reagents & kits
    • 5.2.1 ELISA reagents & kits
    • 5.2.2 ELISPOT reagents & kits
    • 5.2.3 Rapid test reagents & kits
    • 5.2.4 Western blot reagents & kits
    • 5.2.5 Chemiluminescence immunoassay reagents & kits
    • 5.2.6 Immunofluorescence assay reagents & kits
    • 5.2.7 Other reagents & kits
  • 5.3 Analyzers/Instruments
    • 5.3.1 Open ended systems
    • 5.3.2 Closed ended systems

Chapter 6 Market Estimates and Forecast, By Technology, 2018 - 2032 ($ Mn)

  • 6.1 Key trends
  • 6.2 Enzyme-linked immunosorbent assay (ELISA)
  • 6.3 Chemiluminescence immunoassay (CLIA)
  • 6.4 Radioimmunoassay (RIA)
  • 6.5 Immunofluorescence assay (IFA)
  • 6.6 Western blotting
  • 6.7 ELISpot
  • 6.8 Other technologies

Chapter 7 Market Estimates and Forecast, By Specimen, 2018 - 2032 ($ Mn)

  • 7.1 Key trends
  • 7.2 Blood
  • 7.3 Saliva
  • 7.4 Urine
  • 7.5 Other specimens

Chapter 8 Market Estimates and Forecast, By Application, 2018 - 2032 ($ Mn)

  • 8.1 Key trends
  • 8.2 Infectious diseases
  • 8.3 Oncology
  • 8.4 Endocrinology
  • 8.5 Cardiology
  • 8.6 Autoimmune diseases
  • 8.7 Therapeutic drug monitoring
  • 8.8 Other applications

Chapter 9 Market Estimates and Forecast, By End-Use, 2018-2032 ($ Mn)

  • 9.1 Key trends
  • 9.2 Hospitals and clinics
  • 9.3 Diagnostic centers
  • 9.4 Research and academic laboratories
  • 9.5 Homecare settings
  • 9.6 Other end-users

Chapter 10 Market Estimates and Forecast, By Region, 2018 - 2032 ($ Mn)

  • 10.1 Key trends
  • 10.2 North America
    • 10.2.1 U.S.
    • 10.2.2 Canada
  • 10.3 Europe
    • 10.3.1 Germany
    • 10.3.2 UK
    • 10.3.3 France
    • 10.3.4 Spain
    • 10.3.5 Italy
    • 10.3.6 Rest of Europe
  • 10.4 Asia Pacific
    • 10.4.1 Japan
    • 10.4.2 China
    • 10.4.3 India
    • 10.4.4 Australia
    • 10.4.5 South Korea
    • 10.4.6 Rest of Asia Pacific
  • 10.5 Latin America
    • 10.5.1 Brazil
    • 10.5.2 Mexico
    • 10.5.3 Argentina
    • 10.5.4 Rest of Latin America
  • 10.6 Middle East and Africa
    • 10.6.1 South Africa
    • 10.6.2 Saudi Arabia
    • 10.6.3 UAE
    • 10.6.4 Rest of Middle East and Africa

Chapter 11 Company Profiles

  • 11.1 Abbott Laboratories
  • 11.2 Agilent Technologies, Inc.
  • 11.3 Becton Dickinson and Company
  • 11.4 Bio-Rad Laboratories, Inc.
  • 11.5 Danaher Corporation
  • 11.6 F. Hoffmann-La Roche AG
  • 11.7 Hologic Inc.
  • 11.8 Luminex Corporation
  • 11.9 PerkinElmer, Inc.
  • 11.10 QIAGEN
  • 11.11 Sysmex Corporation
  • 11.12 Thermo Fisher Scientific Inc.